Clinical Trial Detail

NCT ID NCT03298451
Title Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

hepatocellular carcinoma

Therapies

Sorafenib

Durvalumab + Tremelimumab

Durvalumab

Age Groups: adult senior

No variant requirements are available.